Jump to main content
Jump to site search

Issue 8, 2012
Previous Article Next Article

Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infection

Author affiliations

Abstract

Sangamides are amide derivatives of sanglifehrin A, a cyclophilin-binding polyketide natural product which is structurally distinct from cyclosporine A. Cyclosporine A is the starting point for the synthesis of cyclophilin inhibitors such as alisporivir, currently in development for the treatment of HCV infection. We report here initial results of the optimisation program which led to identification of the sangamides, compounds that exhibit significantly improved potential for the treatment of chronic HCV infection.

Graphical abstract: Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infection

Back to tab navigation

Supplementary files

Article information


Submitted
06 Sep 2011
Accepted
02 Oct 2011
First published
21 Oct 2011

Med. Chem. Commun., 2012,3, 944-949
Article type
Concise Article

Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infection

S. J. Moss, M. Bobardt, P. Leyssen, N. Coates, U. Chatterji, X. Dejian, T. Foster, J. Liu, M. Nur-e-Alam, D. Suthar, C. Yongsheng, T. Warneck, M. Zhang, J. Neyts, P. Gallay, B. Wilkinson and M. A. Gregory, Med. Chem. Commun., 2012, 3, 944
DOI: 10.1039/C1MD00227A

Search articles by author

Spotlight

Advertisements